Sotabase

Career

· Medical Imaging Intern, Noah Medical2024–2024
· Researcher, UC Berkeley2024–

Publications (38)

Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.
Cancer Research · 2016
683
cited
Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
Nature Medicine · 2019
536
cited
PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
Journal of immunotherapy · 2015
371
cited
Vaccine-induced myeloid cell population dampens protective immunity to SIV.
Journal of Clinical Investigation · 2014
58
cited
Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction
eLife · 2021
56
cited
B7-H4Ig inhibits mouse and human T-cell function and treats EAE via IL-10/Treg-dependent mechanisms.
Journal of Autoimmunity · 2013
52
cited
Early Treatment of NOD Mice With B7-H4 Reduces the Incidence of Autoimmune Diabetes
Diabetes · 2011
51
cited
Control of PD-L 1 Expression by Oncogenic Activation of the AKT – mTOR Pathway in Non – Small Cell Lung Cancer
2016
45
cited
This information is current as Expression Level on T Cell Subsets Novel Mechanism Dependent on PD-1 B 7-DC-Ig Enhances Vaccine Effect by a Ozbun
2012
44
cited
B7-H4 Modulates Regulatory CD4+ T Cell Induction and Function via Ligation of a Semaphorin 3a/Plexin A4/Neuropilin-1 Complex
Journal of Immunology · 2018
33
cited
B7-H4.Ig inhibits the development of type 1 diabetes by regulating Th17 cells in NOD mice.
Cellular Immunology · 2013
30
cited
p 53 / p 21 CIP 1 Cooperate in Enforcing Rapamycin-induced G 1 Arrest and Determine the Cellular Response to Rapamycin 1
2001
18
cited
Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques.
Virology · 2013
14
cited
490 Clinical benefit through Siglec-15 targeting with NC318 antibody in subjects with Siglec-15 positive advanced solid tumors
Journal for ImmunoTherapy of Cancer · 2021
11
cited
Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer
Laboratory Investigation · 2022
11
cited
Development of an Immunohistochemical Assay for Siglec-15
Laboratory Investigation · 2022
10
cited
Arrest and Determine the Cellular Response to Rapamycin 1 Cooperate in Enforcing Rapamycin-induced G CIP 1 p 53 / p 21 Updated
2001
8
cited
Author response: Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction
2021
6
cited
Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia
Cancer Research Communications · 2023
6
cited
Abstract 3151: Quantitative measurement of Siglec-15 expression in non-small cell lung cancer and its association with PD-L1, B7-H4 and tumor infiltrating lymphocytes
Clinical research · 2019
4
cited
Sotabase